Meeting the needs of breast cancer: A nucleolin's perspective
- PMID: 29650282
- DOI: 10.1016/j.critrevonc.2018.03.008
Meeting the needs of breast cancer: A nucleolin's perspective
Abstract
A major challenge in the management of breast cancer disease has been the development of metastases. Finding new molecular targets and the design of targeted therapeutic approaches to improve the overall survival and quality of life of these patients is, therefore, of great importance. Nucleolin, which is overexpressed in cancer cells and tumor-associated blood vessels, have been implicated in various processes supporting tumorigenesis and angiogenesis. Additionally, its overexpression has been demonstrated in a variety of human neoplasias as an unfavorable prognostic factor, associated with a high risk of relapse and low overall survival. Hence, nucleolin has emerged as a relevant target for therapeutic intervention in cancer malignancy, including breast cancer. This review focus on the contribution of nucleolin for cancer disease and on the development of therapeutic strategies targeting this protein. In this respect, it also provides a critical analysis about the potential and pitfalls of nanomedicine for cancer therapy.
Keywords: Breast cancer; Molecular target; Nucleolin; Oncology; Targeted therapy.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
-
RNA-binding protein nucleolin in disease.RNA Biol. 2012 Jun;9(6):799-808. doi: 10.4161/rna.19718. Epub 2012 May 23. RNA Biol. 2012. PMID: 22617883 Free PMC article. Review.
-
Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.Biomaterials. 2015 Nov;69:76-88. doi: 10.1016/j.biomaterials.2015.08.007. Epub 2015 Aug 6. Biomaterials. 2015. PMID: 26283155
-
Molecular dissection of nucleolin's role in growth and cell proliferation: new insights.FASEB J. 1999 Nov;13(14):1911-22. FASEB J. 1999. PMID: 10544174 Review.
-
Perspective on Precision Medicine in Oncology.Pharmacotherapy. 2017 Sep;37(9):988-989. doi: 10.1002/phar.1975. Epub 2017 Aug 7. Pharmacotherapy. 2017. PMID: 28632968 Free PMC article. Review.
-
Precision medicine in breast cancer.Chin Clin Oncol. 2018 Jun;7(3):29. doi: 10.21037/cco.2018.06.04. Chin Clin Oncol. 2018. PMID: 30056731 Review.
Cited by
-
The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway.Cancers (Basel). 2021 Jun 18;13(12):3052. doi: 10.3390/cancers13123052. Cancers (Basel). 2021. PMID: 34207464 Free PMC article.
-
A novel role for nucleolin in splice site selection.RNA Biol. 2022;19(1):333-352. doi: 10.1080/15476286.2021.2020455. Epub 2021 Dec 31. RNA Biol. 2022. PMID: 35220879 Free PMC article.
-
Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration.Ther Adv Med Oncol. 2020 Apr 28;12:1758835920915302. doi: 10.1177/1758835920915302. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32426045 Free PMC article.
-
NIR/pH-triggered aptamer-functionalized DNA origami nanovehicle for imaging-guided chemo-phototherapy.J Nanobiotechnology. 2023 Jun 10;21(1):186. doi: 10.1186/s12951-023-01953-9. J Nanobiotechnology. 2023. PMID: 37301952 Free PMC article.
-
CK2 and the Hallmarks of Cancer.Biomedicines. 2022 Aug 16;10(8):1987. doi: 10.3390/biomedicines10081987. Biomedicines. 2022. PMID: 36009534 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
